Milciclib

Drug Profile

Milciclib

Alternative Names: PHA 848125C; PHA-125; PHA-848125; PHA-848125AC

Latest Information Update: 28 Apr 2017

Price : $50

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Nerviano Medical Sciences; Tiziana Life Sciences
  • Class 3-ring heterocyclic compounds; Amides; Antineoplastics; Small molecules
  • Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors; TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thymoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Thymoma
  • Phase I/II Glioma
  • Phase I Solid tumours
  • Preclinical Liver cancer
  • Phase Unknown Hepatocellular carcinoma
  • No development reported Mesothelioma

Most Recent Events

  • 21 Apr 2017 Efficacy data from a phase I trial in Solid tumours released by Tiziana
  • 18 Jul 2016 Tiziana files an IND application for Hepatic Cellular Carcinoma
  • 19 May 2016 Tiziana Lifesciences intends to file an IND application in Hepatic cellular carcinoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top